source · text/markdown
source_5a01f44ec9764fe9
sha256 13d0fcfbee0656dddf942d380538527384de2dec1d3cb90204ab2656976421c2
by researka:v2 · 2026-06-19 02:17:01.008469+04:00
# Research Synthesis: NAD+ Metabolism Effects — full paper ## Abstract Evidence-honesty note: 8/12 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on NAD+ metabolism effects across 12 included source papers and 804 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 12 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 0 cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that NAD+ metabolism effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-nad_metabolism_effects-v06-DAILY-2026-06-18T16-20-33Z-R2`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-18. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `nad metabolism effects aging` - `nad metabolism effects older adults` - `nad metabolism effects randomized controlled trial` - `nad aging` - `nad older adults` - `nad randomized controlled trial` - `metabolism aging` - `metabolism older adults` - `metabolism randomized controlled trial` - `nicotinamide riboside aging` ### Eligibility criteria - Sources whose primary content addresses nad metabolism effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 175 records in the receipt-candidate union, 55 were classified as source candidates and 12 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 175 | | Classified source candidates | 55 | | No extractable claims | 34 | | None-only claim binding | 13 | | Mixed partial-or-none claim-binding candidates | 46 | | Partial-only claim-binding candidates | 14 | | Strict high-confidence sources | 13 | | Admitted final sources | 12 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Contextual Adjacent Evidence | n=5; claims=146 | no extracted directional signal in 5/5 sources | 3 indirect; 2 review | limited corpus depth in this outcome class | | Cardiometabolic | n=3; claims=306 | unclear signal in 2/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class | | Muscle Function | n=2; claims=202 | unclear signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class | | Frailty | n=1; claims=13 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Safety and Comorbidity | n=1; claims=137 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate. ### Contextual Adjacent Evidence Outcomes 5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=3, review=2. ### Cardiometabolic Outcomes 3 included sources were assigned to this outcome class. Directional coding: null=1, unclear=2. Directness coding: indirect=2, review=1. ### Muscle Function Outcomes 2 included sources were assigned to this outcome class. Directional coding: unclear=2. Directness coding: indirect=2. ### Frailty Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1. ### Safety Comorbidity Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus of 12 sources on NAD+ is dominated by short-duration, small-sample, biomarker-oriented studies and contains no long-term mortality or hard cardiovascular endpoint trial in non-diabetic adults, so any inference about clinical event reduction is unsupported. No source in the corpus reports a trial powered for all-cause mortality, incident diabetes, myocardial infarction, stroke, or fracture, which is the canonical hard-endpoint set against which any anti-aging claim would normally be adjudicated. Several clinically relevant outcome classes are touched by only a single source, which means those findings cannot be cross-validated within the corpus. The cognitive-domain signal likewise rests on a single review-coded source, Yulug 2023 (combined metabolic activators in Alzheimer's disease), and the acute-respiratory-distress-syndrome ferroptosis/NAD+ link is carried by one source, Gao 2026. Single-source outcomes are not internally replicable, so the strength of any cross-domain conclusion that draws on frailty, cognition, or critical-illness endpoints is limited to the internal validity of that one source. Conze 2019 reported a dose of 500 mg. Critically, the corpus contains no source enrolling non-Asian populations in frailty, no source enrolling patients with established cardiovascular disease, and no source enrolling patients with chronic kidney disease, hepatic impairment, or active malignancy. Standard sarcopenia cutoffs such as the EWGSOP2 grip-strength thresholds of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) are not applied inside any source, so claims about NAD+-precursor effects in adults meeting formal sarcopenia criteria cannot be supported by this corpus. Additional corpus sources included animal/preclinical evidence; endpoint scope is narrow and skewed toward pharmacodynamic NAD+ elevation rather than clinical benefit. This biomarker-versus-function divergence — positive NAD+ elevation in Martens 2018, Conze 2019, and Elhassan 2019 against null functional/metabolic outcomes in Connell 2021 and a borderline-null pooled estimate in Chen 2024 — is the principal cross-source disagreement visible in the bundle and is the chief reason surrogate-endpoint caution (Ioannidis 2005) applies directly to this evidence base. Mechanistic and preclinical evidence is being asked to carry claims that the clinical sources in this corpus do not support. Qader 2025 is a systematic review of NAD+-precursor effects in preclinical rodent models of cognitive disease and does not enroll a clinical population, while Gao 2026 is a mechanistic acute-respiratory-distress-syndrome study linking SERPINE1, ferroptosis, and Sirt3-mediated mitochondrial NAD+ disruption. The gap between these mechanism-level findings and the clinical-functional null pattern summarized above means that any mechanistic-to-clinic extrapolation — for example, from rodent cognition data (Qader 2025) or from ARDS mitochondrial biology (Gao 2026) to human cognitive or critical-illness endpoints — is not bridged by any source in the bundle. The corpus also lacks head-to-head precursor comparisons beyond the 14-day Christen 2026 design, and it lacks factorial designs that would isolate the NAD+-precursor contribution in multi-component interventions such as the combined metabolic activators evaluated by Yulug 2023, so the specific contribution of NAD+ elevation to the cognitive signal reported there (P = 0.00001, P = 0.0073, P = 0.0000003, among others) cannot be disentangled within this evidence set. ## Conclusion For NAD+ metabolism effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 12 included sources on NAD+ Metabolism Effects across 5 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 12 curated reference papers, the evidence base for NAD+ shows a context-dependent profile. Null findings dominate: contextual other, cardiometabolic. The NAD+ anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. In animal/preclinical evidence, prior reviews in the corpus (Chen 2024) emphasize convergent signals on NAD+ Metabolism Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | cardiometabolic | 0 | 3 | null, unclear | direct interventional hard-endpoint gap | | frailty | 0 | 1 | null | direct interventional hard-endpoint gap | | muscle function | 0 | 2 | unclear | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 5 | null | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 1 | null | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear | | P2 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P3 | muscle function: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear | | P4 | contextual adjacent evidence: direct interventional hard-endpoint gap | 0 direct and 5 indirect sources; direction profile: null | | P5 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | ### Next-Study Design Recommendation The next high-yield study for NAD+ Metabolism Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot Source directness breakdown: 0/12 retained sources directly address the stated topic and aging-relevant hard endpoints; 12/12 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. ### Source Classification Map - Additional corpus sources included animal/preclinical evidence; Katayoshi 2023: outcome=Cardiometabolic; directness=indirect; tier=B2. - Connell 2021: outcome=Muscle Function; directness=indirect; tier=B2. - Conze 2019: outcome=Safety and Comorbidity; directness=review; tier=B2. - Martens 2018: outcome=Cardiometabolic; directness=indirect; tier=B2. - Yulug 2023: outcome=Contextual Adjacent Evidence; directness=review; tier=B2. - Elhassan 2019: outcome=Muscle Function; directness=indirect; tier=B2. - Qader 2025: outcome=Contextual Adjacent Evidence; directness=review; tier=B2. - Chen 2024: outcome=Cardiometabolic; directness=review; tier=B1. Directional coding note: Null or no extracted directional signal means no coded positive, negative, or mixed effect was extracted for that specific outcome class; it is not an absence-of-support finding. Positive, negative, mixed, unclear, and null are outcome-specific codes, so a bounded rationale can be supported by adjacent or different outcome evidence while another outcome remains null or unclear. Contextual claims contain bibliographic background, mechanism, methods, exposure definitions, or population context rather than effect-direction evidence. When an outcome-class summary uses no extracted directional signal, it should state the source proportion, such as X/Y sources, to avoid ambiguity. The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Additional corpus sources included animal/preclinical evidence; Chen 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Katayoshi 2023; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=null. - Connell 2021; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear. - Conze 2019; tier=B2; directness=review; endpoint=safety comorbidity; direction=null; representative statistic=p ≤ 0.05. - Martens 2018; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear. - Yulug 2023; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null. - Elhassan 2019; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear; representative statistic=P < 0.001. - Qader 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null. - Holmes 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null. - Christen 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=32. - Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=177. - NAD+ -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=148. - Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=137. - Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=97. - Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=69. - Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=54. - A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=34. - Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=19. - The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17. - Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=13. - SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD+ homeostasis and suppressing Sirt3 activity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=7. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Membrez 2024, Studenski 2011, Cesari 2009. ## References - **Katayoshi 2023.** _Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-29787-3. PMID: 36797393. - **Connell 2021.** _NAD+ -Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults._ The Journal of Nutrition, 2021. DOI: 10.1093/jn/nxab193. PMID: 34191033. - **Conze 2019.** _Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults._ Scientific Reports, 2019. DOI: 10.1038/s41598-019-46120-z. PMID: 31278280. - **Martens 2018.** _Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults._ Nature Communications, 2018. DOI: 10.1038/s41467-018-03421-7. PMID: 29599478. - **Yulug 2023.** _Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial._ Translational Neurodegeneration, 2023. DOI: 10.1186/s40035-023-00336-2. PMID: 36703196. - **Elhassan 2019.** _Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures._ Cell Reports, 2019. DOI: 10.1016/j.celrep.2019.07.043. PMID: 31412242. - **Qader 2025.** _A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models._ BMC Neuroscience, 2025. DOI: 10.1186/s12868-025-00937-9. PMID: 40033213. - **Chen 2024.** _Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials._ Current Diabetes Reports, 2024. DOI: 10.1007/s11892-024-01557-z. PMID: 39531138. - **Holmes 2026.** _Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial._ Frontiers in Aging, 2026. DOI: 10.3389/fragi.2026.1773667. PMID: 42211736. - **Christen 2026.** _The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans._ Nature Metabolism, 2026. DOI: 10.1038/s42255-025-01421-8. PMID: 41540253. - **Membrez 2024.** _Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia._ Nature Metabolism, 2024. DOI: 10.1038/s42255-024-00997-x. PMID: 38504132. - **Gao 2026.** _SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD+ homeostasis and suppressing Sirt3 activity._ Redox Biology, 2026. DOI: 10.1016/j.redox.2026.104146. PMID: 42190562. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966. - **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012. PMID: 19349594. - **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "d12f5df9-420a-4155-9804-f21bb6ad2a15",
"title": "Research Synthesis: NAD+ Metabolism Effects \u2014 full paper"
}